Trial Profile
CHARM-03: A Randomized, Open Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel Administered Rectally and Vaginally to HIV-1 Seronegative Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Apr 2022
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Maraviroc (Primary) ; Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms CHARM-03
- 01 Apr 2022 Results published in the AIDS Research and Human Retroviruses
- 07 Mar 2018 Results assessing rectal mucosal immune changes in individuals using MVC in oral tablet, rectal gel or vaginal gel form in the CHARM-03 trial presented at the 25th Conference on Retroviruses and Opportunistic Infections
- 07 Mar 2018 Results presented at the 25th Conference on Retroviruses and Opportunistic Infections